Istradefylline-13C, d3

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Brambilla R, et al. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003 Aug;43 (2) :190-4.|[3]Chen JF, et al. Neuroprotection by caffeine and A (2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001 May 15;21 (10) :RC143.|[4]Kanda T, et al. Combined use of the adenosine A (2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000 Apr;162 (2) :321-7.|[5]Mihara T, et al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3- (4-fluorophenyl) pyrazin-2-yl]-1-isopropylpyridine-2 (1H) -one (ASP5854), in models of Parkinson's disease and cognition. J Pharm|[6]Shiozaki S, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) . 1999 Nov;147 (1) :90-5.